Jafron Biomedical Co's Total Assets for the quarter that ended in Mar. 2024 was ¥5,854 Mil.
Warning Sign:
If a company builds assets at 25.8% a year, faster than its revenue growth rate of 16.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Jafron Biomedical Co's average Total Assets Growth Rate was -5.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 18.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 25.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 31.20% per year.
During the past 13 years, Jafron Biomedical Co's highest 3-Year average Total Assets Growth Rate was 62.80%. The lowest was 18.10%. And the median was 34.15%.
The historical data trend for Jafron Biomedical Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Jafron Biomedical Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jafron Biomedical Co (SZSE:300529) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Jafron Biomedical Co's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Jafron Biomedical Co Total Assets Related Terms
Thank you for viewing the detailed overview of Jafron Biomedical Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Jafron Biomedical Co (SZSE:300529) Business Description
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300529 has been successfully added to your 